semaj83/ctmatch_classification huggingface dataset:
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 12.0-999.0,  Thyroid Cancer Must have histologically confirmed unresectable locally advanced or metastatic MTC and be a candidate for systemic therapy with SOC MKI Must have received no prior systemic anticancer treatment with MKI therapies for advanced or metastatic MTC Must have radiologically confirmed progressive disease within the last 14 months and at least one of the following: [1] A MTC-associated symptom and [2] CLN (Calcitonin) and CEA (carcinoembryonic antigen) level doubling time of less than 24 months Confirmed RET mutation Must be able to swallow an oral medication Must have an ECOG (Eastern Cooperative Oncology Group) Performance Status of 0-2 For women of childbearing potential: agreement to remain abstinent (refrain from heterosexual intercourse) or use appropriate contraception during the treatment period and for the respective period of time after final dose of study drug For men: agreement to remain abstinent (refrain from heterosexual intercourse) or use appropriate contraception during the treatment period and for the respective period of time after final dose of study drug and to refrain from donating sperm  Participants who are pregnant or breastfeeding, or intending to become pregnant during the study within 14 days after the final dose of pralsetinib or within 4 months after the final dose of vandetanib or cabozantinib Have disease that is suitable for surgery or radiotherapy administered with curative intent Have been previously treated with any systemic kinase inhibitor therapy regimens, including a selective RET inhibitor, given for recurrent and/or metastatic disease Have received any radiation therapy within 14 days prior to Day 1 of Cycle 1 and any related toxicity must be resolved to Grade 1 or better Participant's tumor has any additional known primary driver alterations other than RET Have known hypersensitivity to pralsetinib, vandetanib, or cabozantinib, or any of their ingredients Have a history of pneumonitis within the last 12 months Have ongoing treatment with chronic immunosuppressants or systemic steroids >10 mg/day Have any history of hereditary bleeding disorder or any evidence of hematemesis Have had major surgery or invasive dental procedure within 3 weeks prior to Day 1 of Cycle 1
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 18.0-60.0,  Hashimoto Disease Treatment Levothyroxine Vitamin D Deficiency women between 18-45 years old (pre-menopausal stage) men between 18-60 years old BMI between 18.5-34.9 kg/ m2 medical diagnosis of Hashimoto's thyroiditis treatment with levothyroxine (LT4) with stable dose (from four months from the start of the intervention) positive antithyroid antibody (peroxidase and/or thyroglobulin) serum 25 (OH) D levels <20 ng / ml  radioiodine, thyroidectomy, antithyroid treatment disease, condition or drug treatment that alters the immune system or hypothalamic-pituitary-thyroid axis or vitamin D metabolism disorder of kidney, liver, or bone-metabolic function Graves disease, toxic nodular goiter, postpartum thyroiditis, coronary heart disease, epilepsy, cancer, Turner or Down syndrome, primary hyperparathyroidism vitamin D, calcium, complex B, omega-3 supplements pregnant or breastfeeding type 2 diabetes or dyslipidemia with drug treatment at unstable doses intense physical activity
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 18.0-35.0,  Bone Resorption Bone Atrophy Energy Supply; Deficiency Female Athlete Triad Relative Energy Deficiency in Sport To take part in this study, the following must be met Menstrual cycles that are between 21 days in length for at least the previous three cycles Regular length of menstrual cycle (less than six days difference between cycles) for at least the previous three cycles Body mass index between 18.5 kg.m squared Weight stable for the past three months and not currently dieting Participants will not be able to take part in this study if any of the following are met Smoker Pregnant Vegan
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 18.0-75.0,  Hypothyroidism Male or female aged ≥18, ≤75 years old clear diagnosis of primary hypothyroidism Use the same dose of levothyroxine for ≥3 months The levels of thyroid function (TSH, TT4, FT4, TT3, FT3) in hospital laboratory blood tests no more than 6 weeks before participation were within the normal range  regnancy or lactation women affect blood sugar, blood lipid metabolism drugs serious heart disease thyroid malignant tumor history of mental illness
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 15.0-19.0,  Human Immunodeficiency Virus Female Aged 15-19 years HIV-negative (willing to self-test onsite in the presence of the Research Assistant who is also a trained HIV counselor) Has at least one current sexual partner she expects to meet at least twice in the next 3 months (not necessarily to have sex); this will provide opportunity for the participant to suggest/offer testing Resides in Siaya County and does not intend to relocate within 6 months from enrollment, to allow follow up to be completed and to conduct IDI with those selected Willing to be randomized into the partner self-testing or HTS referral groups Reporting no incident of sexual, physical, emotional, or economic abuse in the last 12 months from the partner she intends to offer (Appendix 4) or refer for testing (Appendix 3) in the next 3 months and does not believe the partner will abuse her if she offers the self-test kits or HTS referral coupon Has a male partner who has not tested for 6 months or whose HIV status is unknown to her Agrees to give consent to participate in the study  Male HIV-positive Not willing to self-test onsite under in the presence of the Research Assistant Aged <15 years or >19 years Does not have a current sexual partner or does not expect to meet the partner at least twice in the next 3 months Does not reside in Siaya County or intends to relocate within the next 6 months Not interested in obtaining HIV self-tests or HTS referral coupon for purposes of suggesting testing to their sexual partners Reporting an incidence of sexual, physical, emotional or economic abuse in the last 12 months from the partner she would have offered self-test kit or referred for testing, or believes the partner may subject her to sexual, physical, emotional, or economic abuse if she offered them self-test kit or HTS coupon Has a male partner who tested within the last 6 months Does not give consent to participate in the study
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 18.0-60.0,  Thyrotoxicosis Hypothyroidism Subjects who were newly diagnosed as thyroid dysfunction (thyrotoxicosis or hypothyroidism) or undergoing treatment Subjects who are able to use wearable devices, smart phones, and mobile apps  Subjects with restrictions on normal activities due to diseases other than thyroid dysfunction Subjects who are taking medications affecting heart rate Subjects with diseases affecting heart rate (i.e. arrhythmia)
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 0.0-0.231,  Colic, Infantile Inconsolable crying for more than 3 hours a day, at least 3 days a week for at least 3 weeks Age 2 weeks Gestation equal to or greater than 38 weeks Birth weight equal to or greater than 2,500 grams Weight gain of at least 150 grams. per week Appropriate pediatric general physical examination (height, weight, head circumference and psychomotor development) Sign the informed consent  Signs and / or symptoms of other pathologies Signs of lactose intolerance Having had benefits with the withdrawal of milk from maternal feeding or the use of milk with hydrolyzed casein Having received the subjects and / or siblings, previous treatment with Osteopathy and / or Chiropractic Contraindication to the treatment and / or some of its techniques; presence of congenital malformations
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 0.538-0.692,  Breast Milk Digestion Nutrition Smell Stimulation Preterm Birth Born at 28-36 weeks of PW Birth weight >1000 gr and 5. Apgar score average per minute ≥ 6 Gavage method used in nutrition Intermittent infusion method used in nutrition Not receiving mechanical ventilation / CPAP support No medication or treatment is administered by the nasal route Without nasal obstruction Have not received any established medical diagnosis  Drugs that affect gastrointestinal function (drugs that facilitate gastric emptying and gastrointestinal passage of nutrients by increasing gastrointestinal tract motility, and drugs that reduce gastrointestinal tract motility) Newborns without breast milk Continuous infusion or parenteral feeding method is used in nutrition
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 5.0-55.0,  Virginity Genital Diseases, Female Diagnoses Disease Virgins complaining of Abnormal vaginal bleeding, abnormal discharge , pelvic pain Virgins with Suspected genital tract lesion by examination Virgins with Suspected genital tract lesion by pelvic ultrasound  Sexually Active Patients Suspected or documented Pregnancy Virgin patients with no suspected uterine, cervical or vaginal lesion by pelvic ultrasound Patients unable to communicate effectively
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 18.0-50.0,  Hypothyroidism Pregnancy Related Thyroid Dysfunction Iodine Deficiency Singleton pregnancy Twin pregnancy Free of pre-existing thyroid disease That do not use thyroid interfering medication That did not undergo IVF treatment TPOAb negative  Adolescent pregnancy Patient with pre-existing thyroid disease TPOAb positive Patient using thyroid interfering medication That had IVF treatment
Patient description: A 16-year-old girl came to the clinic complaining of weight gain and abnormal menstrual cycles. Her BMI was 24, but she has gained 5 kg in the past few weeks. She gets tired more frequently and does not have energy to go dancing with her friends. Her lab results were remarkable for high TSH levels (15 mU/L) and low free T4 levels (0.18 ng/dl). Her anti-TPO levels were extremely high (136 IU/ml). She was diagnosed with Hashimoto disease. She does not smoke and she is not sexually active.

Clinical trial eligibility criteria: eligible ages (years): 12.0-999.0,  Hereditary Angioedema (HAE) Participant is aged >= 12 years at the time of the last documented HAE attack in the period Participant has a physician-confirmed diagnosis (or confirmation in medical records) of HAE type I or type II Participant had initiated LTP with lanadelumab during the period Participant provides informed consent or assent prior to the initiation of any study procedures (where required by local regulations)  Participant was enrolled in a therapeutic investigational drug or device trial during the observation period Participant without documented HAE attacks in the pre-index period and/or without available participant diary or systematic documentation of HAE attacks in the medical records during the post index period
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Alcoholism Smoking Meets for alcohol dependence and nicotine dependence Expresses a desire to cut down or stop drinking and smoking  Currently meets for dependence on substances other than alcohol and nicotine Any history of opiate dependence or evidence of current opiate use Significant medical disorders that will increase potential risk or interfere with study participation Liver function tests more than 3 times normal or elevated bilirubin Females who are pregnant, nursing, or not using a reliable method of birth control Meets for a major psychiatric disorder and is in need of or currently undergoing drug therapy Inability to understand and/or comply with the provisions of the protocol and consent form Treatment with an investigational drug during the previous month Chronic treatment with any narcotic-containing medications during the previous month Sensitivity to drug as evidenced by adverse drug experiences especially with narcotic- containing analgesics or opioid antagonists
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  HIV Infections Pregnancy A patient may be eligible for this study if she Is an HIV-positive woman Is receiving care at a study site during the study period or her infant is receiving care at a study site and whose delivery information is available Had a baby on or after January 1, 1998
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 0.0-65.0,  Acquired Immunodeficiency Syndrome Kaposi's Sarcoma Leukemia Lymphoma Tumor Virus Infection HIV Infections Family or personal medical history of neoplasia of an unusual type, pattern, or number. Known or suspected factor(s) predisposing to neoplasia, such as environmental exposure (particularly immunological or virological), genetic or congenital factors (Mendelian traits predisposing to neoplasia, birth defects, and chromosomal anomalies), or unusual demographic features
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Precancerous Condition Stage 0 Cervical Cancer Cytologically confirmed atypical glandular cells of undetermined significance (AGUS) Must be scheduled to undergo complete histologic examination of the cervix by cone biopsy using loop electrosurgical excision procedure with an endocervical curettage, excisional cone biopsy with or without endocervical curettage, or hysterectomy within 6 months of the initial cytologic diagnosis of AGUS No history of endometrial hyperplasia No history of cancer of the endometrium, vagina, or cervix HIV negative No pregnant patients who are at high risk for excessive bleeding or preterm labor if a cone biopsy is performed No prior cytotoxic chemotherapy for vaginal and/or cervical cancer No prior radiotherapy to the vagina or cervix No concurrent radiotherapy to the vagina or cervix No prior hysterectomy
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Cervical Cancer Diagnosis of abnormal Pap test, as indicated by one of the following: Atypical squamous cells of undetermined significance (ASCUS) Low grade squamous intraepithelial lesion (LGSIL) High grade squamous intraepithelial lesion (HGSIL) Visible lesion on cervix by colposcopy Age: Any age Performance status: ECOG 0-4 Life expectancy: Not specified Hematopoietic: Not specified Hepatic: Not specified Renal: Not specified Other: Pregnant or nursing women allowed PRIOR Biologic therapy: Not specified Chemotherapy: Not specified Endocrine therapy: Not specified Radiotherapy: No prior pelvic irradiation Surgery: No prior total hysterectomy
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 18.0-65.0,  Cervical Cancer Cervical Intraepithelial Neoplasia Grade 2 Cervical Intraepithelial Neoplasia Grade 3 Cervical intraepithelial neoplasia (CIN) grade II or III No cytologic, colposcopic, or histologic evidence of invasive squamous cell carcinoma No evidence of glandular atypia on Pap smear, endocervical curettage, or biopsy No inadequate colposcopy (i.e., entire transformation zone cannot be visualized and/or upper limit of a colposcopically abnormal lesion cannot be visualized fully) HIV positive but not currently on antiviral therapy Performance status WBC greater than 4,000/mm^3 Absolute neutrophil count greater than 2,000/mm^3 Platelet count normal Liver enzymes normal
Patient description: A Pap smear in a 54-year-old woman revealed abnormal cervical squamous intraepithelial/glandular lesion. She tested positive for HPV 16. She is sexually active with her husband and has 4 children. She is menopausal and uses no contraception. She smokes and drinks alcohol frequently. She is otherwise healthy. She was offered conization.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Cancer Histologically or cytologically confirmed advanced or metastatic adenocarcinoma Expression of +1 to 3+ HER2/neu on immunohistochemical or immunocytochemistry staining No brain metastases unless all of the following is true Previously treated Asymptomatic Stable dose of decadron No evidence of edema Age: 18 and over Performance status: ECOG 0-2 Life expectancy: At least 12 weeks